Compare SID & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SID | URGN |
|---|---|---|
| Founded | 1941 | 2004 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2002 | 2016 |
| Metric | SID | URGN |
|---|---|---|
| Price | $0.91 | $37.79 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $1.40 | ★ $29.29 |
| AVG Volume (30 Days) | ★ 5.6M | 613.1K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,128,000.00 |
| Revenue This Year | $1.71 | $129.09 |
| Revenue Next Year | $1.58 | $70.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.89 | $12.89 |
| 52 Week High | $2.20 | $37.88 |
| Indicator | SID | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 26.81 | 78.88 |
| Support Level | N/A | $18.58 |
| Resistance Level | $1.43 | N/A |
| Average True Range (ATR) | 0.05 | 1.75 |
| MACD | -0.02 | 0.46 |
| Stochastic Oscillator | 4.62 | 95.82 |
Companhia Siderurgica Nacional is an integrated steel producer. together with its subsidiaries operates in five main business segments: Steel industry: production and marketing of flat and long steels; Mining: extraction, processing and marketing of iron ore, tin, limestone and dolomite; Cement: production and commercialization of bagged and bulk cement, in addition to aggregates, concrete, and other related products; Energy: generation and sale of energy from almost all renewable sources; and Logistics: participations port concessions and fleets of road transport vehicles. The group generates the majority of its revenue from the Steel industry segment. Geographically, it derives a majority of revenue from Asia.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.